Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/11461
Full metadata record
DC FieldValueLanguage
dc.contributor.authorScott, Andrew Men
dc.contributor.authorWolchok, Jedd Den
dc.contributor.authorOld, Lloyd Jen
dc.date.accessioned2015-05-16T01:04:21Z
dc.date.available2015-05-16T01:04:21Z
dc.date.issued2012-03-22en
dc.identifier.citationNature Reviews. Cancer 2012; 12(4): 278-87en
dc.identifier.govdoc22437872en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/11461en
dc.description.abstractThe use of monoclonal antibodies (mAbs) for cancer therapy has achieved considerable success in recent years. Antibody-drug conjugates are powerful new treatment options for lymphomas and solid tumours, and immunomodulatory antibodies have also recently achieved remarkable clinical success. The development of therapeutic antibodies requires a deep understanding of cancer serology, protein-engineering techniques, mechanisms of action and resistance, and the interplay between the immune system and cancer cells. This Review outlines the fundamental strategies that are required to develop antibody therapies for cancer patients through iterative approaches to target and antibody selection, extending from preclinical studies to human trials.en
dc.language.isoenen
dc.subject.otherAnimalsen
dc.subject.otherAntibodies, Monoclonal.pharmacokinetics.pharmacology.therapeutic useen
dc.subject.otherAntigens, Neoplasm.immunology.metabolismen
dc.subject.otherAntineoplastic Agents.pharmacokinetics.pharmacology.therapeutic useen
dc.subject.otherClinical Trials as Topicen
dc.subject.otherDrug Approvalen
dc.subject.otherDrug Carriers.therapeutic useen
dc.subject.otherDrug Resistance, Neoplasmen
dc.subject.otherHumansen
dc.subject.otherImmunomodulationen
dc.subject.otherNeoplasms.drug therapy.metabolismen
dc.subject.otherTissue Distributionen
dc.subject.otherTumor Escapeen
dc.titleAntibody therapy of cancer.en
dc.typeJournal Articleen
dc.identifier.journaltitleNature reviews. Canceren
dc.identifier.affiliationLudwig Institute for Cancer Research; University of Melbourne; and Centre for PET, Austin Hospital, Melbourne, Victoria 3084, Australiaen
dc.identifier.doi10.1038/nrc3236en
dc.description.pages278-87en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/22437872en
dc.type.austinJournal Articleen
local.name.researcherScott, Andrew M
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairetypeJournal Article-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

38
checked on Feb 23, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.